Synaptogenix (SNPX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SNPX Synaptogenix

Watchlist

3.7000
-0.0200-0.54%

Close Aug 16 16:00 ET

4.86MMarket Cap0.36P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Synaptogenix | 10-Q: Q2 2024 Earnings Report
SEC announcementAug 14 16:37 ET · Announcements
Express News | Synaptogenix Announces New Collaboration With Lsu Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
ReutersJul 18 09:00 ET
Synaptogenix Analyst Ratings
BenzingaJul 11 09:06 ET
Maxim Group Upgrades Synaptogenix(SNPX.US) to Buy Rating, Announces Target Price $14
Moomoo NewsJul 11 08:31 ET · Ratings
Express News | Synaptogenix Inc : Maxim Group Raises to Buy From Hold
ReutersJul 11 07:41 ET
Express News | Synaptogenix Announces FDA Authorization Of Its Investigational New Drug Application For Bryostatin-1 Trial In Multiple Sclerosis
BenzingaJun 26 09:13 ET

Comments

Jaguar8

Jul 18 08:02

NEWS

$Synaptogenix (SNPX.US)$
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will com...

Trytosaveabit

Jun 26 08:01

News

$Synaptogenix (SNPX.US)$ Reuters· just
Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis